Transition to Rebif New Formulation

21:39 EDT 22nd October 2014 | BioPortfolio

Summary

To assess patient satisfaction with respect to the incidence of flu-like symptoms in patients with multiple sclerosis transitioned from current Rebif (subcutaneously injected interferon beta-1a, 44mcg three-times-weekly) to the new formulation of Rebif while receiving ibuprofen either prophylactically or only when necessary (PRN) after the occurance of flu-like symptoms.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Conditions

Relapsing Multiple Sclerosis

Intervention

Rebif New Formulation + prophylactically Ibuprofen, Rebif New Formulation + ibuprofen PRN

Location

Local Medical Information
Paris
France

Status

Completed

Source

EMD Serono

Results (where available)

View Results

Links

Clinical Trials [1001 Associated Clinical Trials listed on BioPortfolio]

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)

The rationale of this study is to assess the safety profile, efficacy and adherence to Rebif® New Formulation in real life settings with a multinational approach, as well as the impact of...

REbif FLEXible Dosing in Early Multiple Sclerosis (MS)

The primary objective of the study is to evaluate the effect of Rebif New Formulation 44 mcg (tiw and ow) versus placebo on the time to conversion to McDonald MS in patients with a first c...

Study Comparing the Efficacy ofTwo Ibuprofen Formulations

This is a study of healthy volunteers to compare how quickly different ibuprofen products relieve dental pain.

Study Evaluating a Novel Ibuprofen Formulation in the Treatment of Dental Pain

This study will compare the analgesic efficacy of a single-dose of a novel ibuprofen formulation to placebo and two formulations of standard ibuprofen in the treatment of post-surgical den...

Pharmacokinetics of 3 Formulations of Ibuprofen Suppositories

The purpose of this study is to compare the pharmacokinetic and bioavailability characteristics of two test formulations of ibuprofen for rectal administration with the profile of a market...

PubMed Articles [1202 Associated PubMed Articles listed on BioPortfolio]

An investigation into the drug release from ibuprofen matrix tablets with ethylcellulose and some poly-acrylate polymers.

This study was performed to achieve sustained-release Ibuprofen matrix tablets with a zero-order release kinetic while most of the previous formulations have shown Higuchi release kinetic. Considering...

Randomized comparative trial of efficacy of paracetamol, ibuprofen and paracetamol-ibuprofen combination for treatment of febrile children.

Paracetamol and ibuprofen are widely used for fever in children as monotherapy and as combined therapy. None of the treatments is proven clearly superior to others. Hence, the study was planned to com...

Development of ibuprofen nanoliposome for transdermal delivery: Physical characterization, in vitro/in vivo studies, and anti-inflammatory activity.

Objective: Ibuprofen is an established non-steroidal anti-inflammatory drug commonly used for general inflammation. However, it causes gastrointestinal troubles when administered orally, thereby decre...

Nonionic surfactant-based vesicular system for transdermal drug delivery.

Abstract Objective: The objective of this study was to formulate and evaluate the Ibuprofen niosomal formulation as a transdermal drug delivery system. Materials and methods: Niosomes were prepared by...

Stabilisation of amorphous ibuprofen in Upsalite, a mesoporous magnesium carbonate, as an approach to increasing the aqueous solubility of poorly soluble drugs.

One attractive approach to increase the aqueous solubility and thus the bioavailability of poorly soluble drugs is to formulate them in their amorphous state since amorphous compounds generally exhibi...

Medical and Biotech [MESH] Definitions

A nonsteroidal anti-inflammatory agent with analgesic properties used in the therapy of rheumatism and arthritis.

An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.

An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.

Disorders in which phagocytic cells cannot kill ingested bacteria; characterized by frequent recurring infection with formulation of granulomas.

A field of biological research combining engineering in the formulation, design, and building (synthesis) of novel biological structures, functions, and systems.

More From BioPortfolio on "Transition to Rebif New Formulation"

Search BioPortfolio:
Loading